The world must wait until June to find out more about Stemcentrx Inc.'s lead, late-stage asset, rovalpituzumab tesirine (Rova-T), an antibody-drug conjugate (ADC), but Abbvie Inc. already has decided to bet high, taking over the company in a deal that could be worth almost $10 billion.